Drug Trial Radar · NCT06333808
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
577
Actual
Start
Mar 25, 2024
Primary completion
Oct 27, 2025
Study completion Dec 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed). The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.
Conditions
- HIV-1-infection
Interventions
Bictegravir/Lenacapavir (BIC/LEN) FDCDrug
Tablets administered orally without regard to food
LenacapavirDrug
Tablets administered orally without regard to food
B/F/TAFDrug
Tablets administered orally without regard to food
Placebo to match B/F/TAFDrug
Tablets administered orally without regard to food
Placebo to match BIC/LEN FDCDrug
Tablets administered orally without regard to food
Placebo to match LenacapavirDrug
Tablets administered orally without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot AlgorithmTime frame: Week 48
Locations
104 sites in 14 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians
Phoenix, Arizona
Be Well Medical Center
Berkeley, California
Pacific Oaks Medical Group
Beverly Hills, California
Ruane Clinical Research Group Inc.
Los Angeles, California
Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
Oakland, California
BIOS Clinical Research
Palm Springs, California
UCSD Anti Viral Research Centre (AVRC)
San Diego, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Mills Clinical Research
West Hollywood, California
Public Health Institute at Denver Health
Denver, Colorado
Yale University School of Medicine (study visits)
New Haven, Connecticut
Midland Florida Infectious Diseases Specialists, PL - Orange City
DeLand, Florida
Therafirst Medical Center
Fort Lauderdale, Florida
CAN Community Health
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
AIDS Healthcare Foundation - The Kinder Medical Group
Miami, Florida
Schiff Center for liver Diseases/University of Miami
Miami, Florida
Floridian Clinical Research
Miami Lakes, Florida
Orlando Immunology Center
Orlando, Florida
Bliss Healthcare
Orlando, Florida
AHF Pensacola
Pensacola, Florida
CAN community Health
Sarasota, Florida
Triple O Research Institute, P.A.
West Palm Beach, Florida
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Mercer University, Department of Internal Medicine
Macon, Georgia
Claudia T Martorell MD LLC dba The Research Institute
Springfield, Massachusetts
Henry Ford Health
Detroit, Michigan
KC Care health Center
Kansas City, Missouri
Southampton Community Healthcare, Inc.
St Louis, Missouri
ID Care, LLC
Hillsborough, New Jersey
Saint Michael's Medical Center
Newark, New Jersey
New Jersey Medical School - Clinical Research Center
Newark, New Jersey
South Jersey Infectious Disease
Somers Point, New Jersey
AXCES Research Group, LLC
Santa Fe, New Mexico
New York-Presbyterian Queens
Flushing, New York
Montefiore Medical Center
The Bronx, New York
The Brody School of Medicine at East Carolina University , ECU Adult Specialty Care
Greenville, North Carolina
Rosedale Health and Wellness
Huntersville, North Carolina
Philadelphia FIGHT Community Health Centers
Philadelphia, Pennsylvania
Medical University of South Carolina (MUSC) Research Nexus
Charleston, South Carolina
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.